parthenolide | 604004-27-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: parthenolide
• 英文别名: Oxireno[9,10]cyclodeca[1,2-b]furan-9(1aH)-one, 2,3,6,7,7a,8,10a,10b-octahydro-1a,5-dimethyl-8-methylene-, (1aR,4E,7aS,10aS,10bR)-；(1S,2R,4R,7Z,11S)-4,8-dimethyl-12-methylidene-3,14-dioxatricyclo[9.3.0.02,4]tetradec-7-en-13-one
• CAS: 604004-27-5
• 化学式: C₁₅H₂₀O₃
• 分子量: 248.322
• InChiKey: KTEXNACQROZXEV-ZRPLFPEYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  18
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  38.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  parthenolide 在 叔丁基过氧化氢 、 selenium(IV) oxide 作用下， 以 二氯甲烷 为溶剂， 以80%的产率得到melampomagnolide B
  参考文献：
  名称：

  几种倍半萜内酯模型的潜在化感作用

  摘要：

  摘要 已制备并测试了 12 种天然和合成倍半萜内酯的集合，这些内酯具有 eudesmanolide、melampolide、cis、cis-germacranolide 和 guaianolide 骨架。评估了该集合的10 -4 -10 -9 M 处的一系列水溶液的效果。讨论了与其活动相关的具体结构要求。已使用SeO 2 和叔丁基过氧化氢从木香内酯、小白菊内酯和脱氢木香内酯合成天然倍半萜内酯soulangianolide A、melampomagnolide A和B、zaluzanin C和isozaluzanin C。合成化合物的结构通过核磁共振光谱确定。

  DOI：

  10.1016/0031-9422(92)80343-d

文献信息

• USE OF PARTHENOLIDE DERIVATIVES AS ANTILEUKEMIC AND CYTOTOXIC AGENTS
  申请人：University of Kentucky

  公开号：US20150259356A1

  公开（公告）日：2015-09-17

  The present invention provides compounds of the formula (I) wherein: X 1 , X 2 and X 3 are heteroatoms; R 4 , R 5 , R 6 , R 7 , R 8 , R 9 and R 10 are independently selected from H, halo, —OH, —NO 2 , —CN and optionally substituted aliphatic, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; and Z is optionally substituted C 1-8 straight-chained or branched aliphatic, optionally containing 1 or more double or triple bonds, wherein one or more carbons are optionally replaced by R* wherein R* is optionally substituted cycloalkyl, heterocycloalkyl, aryl or heteroaryl; an amino acid residue, H, —CN, —C(O)—, —C(O)C(O)—, —C(O)NR 1 —, —C(O)NR 1 NR 2 —, —C(O)O—, —OC(O)—, —NR 1 CO 2 —, —O—, —NR 1 C(O)NR 2 —, —OC(O)NR 1 —, —NR 1 NR 2 —, —NR 1 C(O)—, —S—, —SO—, —SO 2 —, —NR 1 —, —SO 2 NR 1 —, —NR 1 R 2 , or —NR 1 SO 2 —, wherein R 1 and R 2 are independently selected from H and optionally substituted aliphatic, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; or where R* is NR 1 R 2 , R 1 and R 2 optionally together with the nitrogen atom form an optionally substituted 5-12 membered ring, said ring optionally comprising 1 or more heteroatoms or a group selected from —CO—, —SO—, —SO 2 — and —PO—; or a pharmaceutically acceptable salt, ester or prodrug thereof.

  本发明提供了以下式（I）的化合物： 其中： X1，X2和X3是杂原子； R4，R5，R6，R7，R8，R9和R10分别选自H，卤素，—OH，—NO2，—CN和可选地取代的脂肪族，环烷基，杂环烷基，芳基或杂芳基；以及 Z是可选地取代的C1-8直链或支链脂肪族，可选地含有1个或多个双键或三键，其中一个或多个碳原子可选地被R*取代，其中R*是可选地取代的环烷基，杂环烷基，芳基或杂芳基；氨基酸残基，H，—CN，—C（O）—，—C（O）C（O）—，—C（O）NR1—，—C（O）NR1NR2—，—C（O）O—，—OC（O）—，—NR1CO2—，—O—，—NR1C（O）NR2—，—OC（O）NR1—，—NR1NR2—，—NR1C（O）—，—S—，—SO—，—SO2—，—NR1—，—SO2NR1—，—NR1R2，或—NR1SO2—，其中R1和R2分别选自H和可选地取代的脂肪族，环烷基，杂环烷基，芳基或杂芳基；或者当R*为NR1R2时，R1和R2可选地与氮原子一起形成一个可选地取代的5-12成员环，所述环可选地包含1个或多个杂原子或从—CO—，—SO—，—SO2—和—PO—中选择的基团；或者其药学上可接受的盐，酯或前药。
• USES OF SESQUITERPENE LACTONE COMPOUNDS AND THEIR DERIVATIVES IN DRUGS PREPARATION
  申请人：ACCENDATECH

  公开号：US20160367525A1

  公开（公告）日：2016-12-22

  The present invention relates to the uses of sesquiterpene lactone compounds and their derivatives in preparing drugs. It belongs to the field of drug technology, specifically relates to the uses of the compounds of Formula (I) in preparing the drugs, especially the uses in preparing the drugs to treat rheumatoid arthritis and treat cancers through inhibiting cancer stem cells.

  本发明涉及倍半萜内酯化合物及其衍生物在制备药物中的用途。它属于药物技术领域，具体涉及在制备药物中使用式(I)化合物，特别是在制备用于治疗类风湿关节炎和通过抑制癌干细胞治疗癌症的药物中的用途。
• Synthesis and Cytotoxic Activity of the Products of Addition of Thiophenol to Sesquiterpene Lactones
  作者：A. V. Semakov、L. V. Anikina、S. G. Klochkov

  DOI：10.1134/s106816202104018x

  日期：2021.7

  sesquiterpene lactones modified at the lactone ring with a thiophenol residue have been synthesized. The resulting conjugates with thiophenol have capacity for the oxidation–elimination reaction by the action of ROS of a tumor cell with the release of initial cytotoxic lactones. It has been proposed to use the resulting sulfur-containing conjugates as ROS-activated prodrugs of sesquiterpene lactones. The antiproliferative

  摘要—— 已经合成了在内酯环上用苯硫酚残基修饰的倍半萜内酯衍生物。由此产生的与苯硫酚的结合物具有通过肿瘤细胞的 ROS 的作用与初始细胞毒性内酯的释放进行氧化消除反应的能力。已提议将所得含硫缀合物用作倍半萜内酯的 ROS 活化前药。已在肿瘤和假性正常细胞系上检查了缀合物的抗增殖特性。偶联物的细胞毒性低于母体内酯；然而，在某些情况下，如阿兰内酯与青蒿素的结合物，它在所有测试的肿瘤细胞系中保持中等。
• Compounds for inhibiting beta-amyloid production and methods of identifying the compounds
  申请人：Mullan J. Michael

  公开号：US20070037855A1

  公开（公告）日：2007-02-15

  Provided are compounds useful for treating diseases associated with a cerebral accumulation of Alzheimer's amyloid, such as Alzheimer's disease. Also provided are methods for screening for such compounds, by measuring capacitative calcium entry in cells which optionally overexpress APP or a fragment thereof. Also provided are methods of treating or reducing the risk of developing β-amyloid production, β-amyloid deposition, β-amyloid neurotoxicity (including abnormal hyperphosphorylation of tau) and microgliosis associated with cerebral accumulation of Alzheimer's amyloid by administering therapeutically effective amounts of compounds which decrease β-amyloid production and capacitative calcium entry in cells. Further provided are methods for diagnosing diseases associated with cerebral accumulation of Alzheimer's amyloid in animals or humans by administering diagnostically effective amounts of compounds which inhibit capacitative calcium entry in cells.

  提供的化合物可用于治疗与阿尔茨海默淀粉样蛋白在大脑中积累有关的疾病，例如阿尔茨海默病。还提供了筛选此类化合物的方法，通过测量细胞中的电容性钙离子进入，其中细胞可以选择性地过度表达APP或其片段。还提供了通过给予治疗有效量的化合物来治疗或降低β-淀粉样蛋白产生、β-淀粉样蛋白沉积、β-淀粉样蛋白神经毒性（包括tau的异常高磷酸化）和与阿尔茨海默淀粉样蛋白在大脑中积累有关的微胶质细胞增生的方法。此外，还提供了通过给动物或人类施用诊断有效量的抑制电容性钙离子进入细胞的化合物来诊断与阿尔茨海默淀粉样蛋白在大脑中积累有关的疾病的方法。
• AGONISTS OF BITTER TASTE RECEPTORS AND USES THEREOF
  申请人：Behrens Maik

  公开号：US20100130498A1

  公开（公告）日：2010-05-27

  The present invention relates to agonists of the human bitter-taste receptors hTAS2R14, hTAS2R10 and hTAS2R4 and their role in bitter taste transduction. The invention also relates to methods for identifying molecules that modulate, e.g. suppress, or enhance hTAS2R14, hTAS2R10 and hTAS2R4 bitter taste transduction or bitter taste response.